Trials / Conditions / Neurofibromatosis 2

Neurofibromatosis 2

19 registered clinical trials studyying Neurofibromatosis 2 — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Unknown	89Zr-Bevacizumab PET/CT Imaging in NF2 Patients NCT05685836	Leiden University Medical Center	—
Unknown	Vestibular Precision: Physiology & Pathophysiology NCT04890132	Massachusetts Eye and Ear Infirmary	N/A
Completed	Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Ves NCT04283669	University of Alabama at Birmingham	Phase 2
Unknown	Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15 NCT03893643	Centre Hospitalier Universitaire de Nice	—
Active Not Recruiting	Study of Aspirin in Patients With Vestibular Schwannoma NCT03079999	Massachusetts Eye and Ear Infirmary	Phase 2
Completed	Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing NCT03406208	Massachusetts General Hospital	N/A
Terminated	Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors NCT03095248	Children's Hospital Medical Center, Cincinnati	Phase 2
Completed	Reliability of Functional Outcome Measures in Neurofibromatosis 2 NCT03617276	Guy's and St Thomas' NHS Foundation Trust	—
Completed	AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas NCT02831257	Massachusetts General Hospital	Phase 2
Completed	Resiliency Training for Patients With NF2 Via Videoconferencing With Skype NCT02811718	Massachusetts General Hospital	N/A
Completed	Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype NCT02298270	Massachusetts General Hospital	N/A
Recruiting	Neurofibromatosis (NF) Registry Portal NCT01885767	The Children's Tumor Foundation	—
Completed	Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) NCT01490476	Assistance Publique - Hôpitaux de Paris	Phase 2
Completed	Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors NCT00973739	NYU Langone Health	Phase 2
Terminated	PTC299 for Treatment of Neurofibromatosis Type 2 NCT00911248	PTC Therapeutics	Phase 2
Completed	Concentration and Activity of Lapatinib in Vestibular Schwannomas NCT00863122	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	EARLY_Phase 1
Unknown	NF2 Natural History Consortium NCT00004483	House Ear Institute	—
Completed	An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors NCT00030043	FDA Office of Orphan Products Development	Phase 1
Completed	Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibroma NCT00004437	FDA Office of Orphan Products Development	Phase 2